Europe's Pharma Giants Just Sent a 911 Call to Brussels

A Bureaucracy Problem Disguised as a Competitiveness Problem

One of the sharpest complaints in the letter targets clinical trial timelines, and it's easy to see why.

Under Europe's Clinical Trials Regulation, a standard application is supposed to be reviewed in about 60 days. In practice? The median time from submission to decision hit 106 days as of September 2025, according to the EU's own tracking data. Industry group EFPIA says the real average now exceeds 110 days.

For context, other major regions (including the U.S. and China) typically operate in the 30 to 60 day range for comparable approvals. So a company designing a global trial faces a simple question: why start in Europe when you can get going twice as fast somewhere else?

The bottlenecks aren't mysterious. Clock-stopping requests for information, fragmented ethics review processes across member states, and inconsistent national practices all pile up. Germany, to its credit, can push mono-national applications through in 26 to 31 days. But the EU-wide average tells a different story. It's death by a thousand committee meetings.

Brussels Has a Plan. The CEOs Say It's Not Enough.

To be fair, the European Commission isn't ignoring the problem. Its Life Sciences Strategy aims to make Europe the most attractive place for life sciences by 2030. A proposed European Biotech Act would streamline regulatory pathways and speed up product authorizations. A second-stage biotech ecosystem proposal is expected in 2026.

Those are real steps. But the nine chairs essentially said: nice start, not nearly enough.

Their core argument is that EU-level action alone won't fix things, because member states control the health budgets. A regulation from Brussels means little if individual countries still penny-pinch on reimbursement, drag their feet on digital health policy, or cap what they'll pay for innovative treatments. The reform package has to work at both the continental and national level, or it won't work at all.

Analysts reading the letter see it as a calculated pressure campaign. The timing matters: these executives want to shape policy before even more investment quietly migrates across the Atlantic or eastward to Asia. One recurring phrase in the coverage captures the mood perfectly: Europe risks a "slow agony" if it doesn't act.

Why This Actually Matters to You

If you're an investor, a biotech founder, or anyone building a career in drug development, this letter is a flashing signal about where the money is going (and where it isn't).

Europe still has world-class science, outstanding universities, and deep therapeutic expertise. Nobody disputes that. But science without capital is just a really expensive hobby. And when nine chairs who represent companies with a combined market cap in the hundreds of billions publicly warn that conditions are deteriorating, the smart money listens.

The stat that should haunt European policymakers is simple: the continent now captures only about 7% of global health-biotech venture capital. Seven percent. For a region with 450 million people and some of the best research institutions on the planet, that number is almost comically low.

The letter won't fix anything by itself. Open letters rarely do. But it does something important: it makes the problem impossible to ignore. Nine companies that compete fiercely with each other just agreed, publicly, that their shared home market is broken.

When your fiercest rivals team up to send the same distress signal, the house really might be on fire.

The $4 Billion ADC Bet That Just Hit a Wall

Daiichi Sankyo and Merck pulled their FDA application for a lung cancer ADC just two weeks before the decision date. The reason signals a seismic shift in how the FDA evaluates accelerated approvals, and dozens of ADC programs should be worried.